Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Ovarian Cancer
Ovarian Cancer Year In Review Introduction
Read More
First-Line Maintenance Setting in Patients with Recurrent Ovarian Cancer: Individualized Starting Dose of Niraparib Recommended
Read More
Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer
Read More
A Systematic Review of Robotic Interval Debulking Surgery for Advanced Epithelial Ovarian Cancer
Read More
Phase 2 OVARIO Study: Promising Survival Rates with Niraparib plus Bevacizumab in Women with Advanced Ovarian Cancer
Read More
Starting Dose of Rucaparib in Patients with Recurrent Ovarian Cancer Based on a Pooled Analysis
Read More
The Efficacy of Niraparib in Patients with Advanced Ovarian Cancer Extends to All Biomarker Subgroups
Read More
Phase 3 SOLO1 Subgroup Analysis Based on Olaparib-Treated, Low- and High-Risk Patients with Ovarian Cancer and BRCA Mutation
Read More
Risk of Secondary Hematologic Malignancy Not Significantly Increased by PARP Inhibitors
Read More
NOVA Clinical Trial versus Real-World Data: Niraparib Treatment Outcomes in Patients with BRCA–Wild-Type, Platinum-Sensitive, Recurrent Ovarian Cancer
Read More
1
2
3
4
5
6
7
Page 4 of 13
Results 31 - 40 of 122